Absence of acute rejection using basiliximab with triple immunosuppression in cadaveric kidney recipients in first three months.
Kandus
A
A
Department of Nephrology, University Medical Center, Ljubljana, Slovenia.
Kovac
D
D
Buturović-Ponikvar
J
J
Ponikvar
R
R
Koselj
M
M
Lindic
J
J
Kmetec
A
A
Bren
A F
AF
D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D012727:Sex Characteristics; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab